Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
5.14 (1y: -47%)
Market Cap 131.98 M P/E(ttm)
Enterprise Value 138.86 M P/B
OMER- NAS (USA)
Omeros Corporation
Not Rated
Top Ranked Predictable Companies
$5.14
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 1.112
OMER's Cash to Debt is ranked lower than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMER: 1.112 )
OMER' s 10-Year Cash to Debt Range
Min: 1.11   Max: 23.84
Current: 1.11
1.11
23.84
Equity to Asset -0.246
OMER's Equity to Asset is ranked lower than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. OMER: -0.246 )
OMER' s 10-Year Equity to Asset Range
Min: -4.21   Max: 0.7
Current: -0.25
-4.21
0.7
F-Score: 3
Z-Score: -18.51
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -612.50
OMER's Operating margin (%) is ranked lower than
73% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. OMER: -612.50 )
OMER' s 10-Year Operating margin (%) Range
Min: -2096.2   Max: -605.9
Current: -612.5
-2096.2
-605.9
Net-margin (%) -638.4
OMER's Net-margin (%) is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. OMER: -638.4 )
OMER' s 10-Year Net-margin (%) Range
Min: -2036.5   Max: -631
Current: -638.4
-2036.5
-631
ROA (%) -144.7
OMER's ROA (%) is ranked lower than
88% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. OMER: -144.7 )
OMER' s 10-Year ROA (%) Range
Min: -144.7   Max: -34
Current: -144.7
-144.7
-34
Revenue Growth (%) 5.7
OMER's Revenue Growth (%) is ranked lower than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OMER: 5.7 )
OMER' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 5.7
Current: 5.7
0
5.7
EBITDA Growth (%) -14.4
OMER's EBITDA Growth (%) is ranked lower than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. OMER: -14.4 )
OMER' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -14.4
Current: -14.4
EPS Growth (%) -14.1
OMER's EPS Growth (%) is ranked lower than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. OMER: -14.1 )
OMER' s 10-Year EPS Growth (%) Range
Min: 0   Max: -14.1
Current: -14.1
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q1 2012

OMER Guru Trades in Q1 2012

Jim Simons 66,000 sh (+534.62%)
» More
Q2 2012

OMER Guru Trades in Q2 2012

Jim Simons 154,100 sh (+133.48%)
» More
Q3 2012

OMER Guru Trades in Q3 2012

Jim Simons Sold Out
» More
Q1 2013

OMER Guru Trades in Q1 2013

Jim Simons 91,037 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OMER



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/S 23.36
OMER's P/S is ranked lower than
73% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. OMER: 23.36 )
OMER' s 10-Year P/S Range
Min: 16.3   Max: 118.71
Current: 23.36
16.3
118.71
EV-to-EBIT -3.58
OMER's EV-to-EBIT is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. OMER: -3.58 )
OMER' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.58

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 137.9
OMER's Price/Net Current Asset Value is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. OMER: 137.9 )
OMER' s 10-Year Price/Net Current Asset Value Range
Min: 8.6   Max: 395
Current: 137.9
8.6
395
Price/Median PS Value 0.6
OMER's Price/Median PS Value is ranked higher than
78% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. OMER: 0.6 )
OMER' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.4
Current: 0.6
0.6
2.4

Business Description

Omeros Corporation was incorporated in the state of Washington on June 16, 1994. It is a clinical-stage Biopharmaceutical Company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery (tm) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery (tm) platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. The Company has currently four PharmacoSurgery (tm) programs in clinical development. Its main product candidate, OMS103HP, for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain, is in Phase 3 clinical trials at orthopedic sports medicine centers throughout the U.S. and Canada. In addition to its PharmacoSurgery(tm ) platform, the Company has leveraged its expertise in inflammation and the central nervous system to build a deep and diverse pipeline of preclinical programs targeting large markets. The Company has retained all manufacturing, marketing and distribution rights for each of its product candidates and programs. Its PharmacoSurgery(tm) product candidates are designed to modulate the molecular mechanisms of pathologic conditions rather than just treating its symptoms. The Company is developing its current PharmacoSurgery(tm) product candidates, OMS103HP- Arthroscopy, OMS302- Ophthalmology, and OMS210- Urology by 'leveraging generics.' Omeros' main product candidate, OMS103HP, is in two clinical programs at orthopedic sports medicine centers throughout the U.S. and Canada. The first program is a Phase 3 program evaluating OMS103HP's safety and ability to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS302 is being developed for use during ophthalmological procedures, including cataract and other lens replacement surgery. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) each with well-known safety and pharmacologic profiles. OMS201 is being developed for use during urological surgery. OMS201 is a proprietary combination of an anti-inflammatory agent and a smooth muscle relaxant.
Company Website
SEC Reports
Industry: Biotechnology
Compare:
Traded in other countries:3O8.Germany
» More Articles for OMER

Headlines

Articles On GuruFocus.com
A Bearish Speculative Options Bet Jul 22 2011 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial